Aiming to become the first Japanese bio-accelerator, Ciconia Bioventures has started screening potential drug candidates from more than one hundred assets emerging from preclinical research at mostly academic partners.
The company, a joint venture between Takeda, Astellas and Sumitomo Mitsui Bank, is now in discussions with over 40 academic/non-academic organizations and has JPY200m ($1
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?